Prs17: Epidemiology and Costs of Bronchial Asthma and Chronic Bronchitis in Germany

Weissflog, D

doi:10.1016/s1098-3015(11)70713-6

Cited by 8 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results from the present cross-sectional study confirm and extend findings from previous assessments of medical resource utilisation and the cost of asthma in Italy [20,21,24] and other European countries [3,6,7,25,26]. Physician-classified asthma severity, using the GINA classification, is clearly associated with patient-reported symptomatology and resource use.…”

Section: Discussionsupporting

confidence: 86%

“…Similar or almost identical estimates have been calculated for other countries, including Spain [6] and France [14], but some cost-of-asthma analyses found that prescription medicines made up more than 50% of all direct costs [15,25,26]. To some extent, these differences may be explained by methodological factors.…”

Section: Discussionsupporting

confidence: 55%

“…To some extent, these differences may be explained by methodological factors. For example, WEISSFLOG et al [26] reported that outpatient prescribed medicines accounted for 55% of direct asthma costs in Germany, but did not include outpatient physician services in the calculation, due to a lack of adequate data. Elimination of this cost component will probably have resulted in overestimation of the other components.…”

Section: Discussionmentioning

confidence: 99%

“…The present study was based on a specifically designed questionnaire with a short recall period for most outcomes surveyed. This allowed for the assessment of variables such as effectiveness of paid work, or quality of life-associated symptoms, which cannot be measured by retrospective chart review [3] or medical claims data [25,26,30].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Asthma severity and medical resource utilisation

Antonicelli¹,

Bucca²,

Neri³

et al. 2004

Eur Respir J

260

149

View full text Add to dashboard Cite

Asthma represents a growing public health problem and the cost of asthma has been rising in many countries. The aim of this study was to estimate the direct and indirect cost of asthma among adult patients in Italy, and to assess the relationship between healthcare resource use and asthma severity according to the Global Initiative for Asthma (GINA) classification system.A multicentre cross-sectional study was conducted in 16 Italian hospital-based specialised asthma clinics. Data collection was based on self-administered questionnaires and took place during the period May 1-November 30, 1999, and 500 consecutive patients with asthma, aged 18-55 yrs, were enrolled during regularly scheduled visits. Direct costs (drugs, physician visits, emergency service use and hospitalisation), indirect costs (loss of paid workdays) and total costs were determined in euros (J) for 1999.Patients with more severe disease, as classified by the GINA guideline, exhibited more night-time and daytime symptoms and were more limited in performing normal daily activities. The mean total cost of asthma per patient per year was estimated to be J1,260; drug costs accounted for 16%, physician costs 12%, emergency service and hospitalisation costs 20% and indirect costs 52% of the mean cost. Stratified by severity, the total annual cost per patient amounted to J720, J1,046, J1,535 and J3,328 for patients with intermittent, mild persistent, moderate persistent and severe persistent asthma, respectively.Asthma severity, as determined by the Global Initiative for Asthma classification, is significantly associated with symptoms, limitations in normal daily activities, asthmarelated medical resource utilisation and both direct and indirect costs. Asthma control is not only a clinical but also an economic imperative.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Asthma severity and medical resource utilisation

Antonicelli¹,

Bucca²,

Neri³

et al. 2004

Eur Respir J

260

149

View full text Add to dashboard Cite

show abstract

“…From the societal perspective, the economic impact of asthma in Germany was J2.62 billion in 1992 [7] and J2.97 billion in 1996 [8], of which 61.4% were direct costs [7]. Analysis of 1992 data shows a positive correlation between illness severity and total cost.…”

mentioning

confidence: 99%

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1‐yr retrospective study

Schramm¹,

Ehlken²,

Smala³

et al. 2003

Eur Respir J

129

View full text Add to dashboard Cite

The purpose of this study was to evaluate the cost of illness of moderateto-severe atopic asthma and/or seasonal allergic rhinitis (SAR) in Germany from the perspective of third-party payers (TPP) and patients.Five-hundred patients (276 children/adolescents) with moderate-to-severe asthma and/ or SAR were included in this cross-sectional study. Information was collected using a specific patient questionnaire and the abstraction of patient records.Overall, annual costs per patient increased with the severity of atopic asthma and if it was associated with SAR. The average annual cost of SAR was J1,089 per child/ adolescent and J1,543 per adult. Annual costs of severe asthma plus SAR increased to J7,928 per child/adolescent and to J9,287 per adult. For TPPs, the main cost drivers were medication, hospitalisation, and rehabilitation. The most significant costs for patients were household modifications. For children/adolescents, 60-78% of the expenditures were direct costs, while in adults, 58% of expenditures were indirect costs. It was also observed that patients with moderate and severe asthma used inhaled corticosteroids less frequently than recommended by treatment guidelines.In summary, the total cost for patients increases with the severity of atopic asthma and/or seasonal allergic rhinitis and indirect costs represent a large proportion of the total cost.

show abstract

First approaches to the monetary impact of environmental health disturbances in Germany

Haucke

Brückner

2010

Health Policy

View full text Add to dashboard Cite

Prs17: Epidemiology and Costs of Bronchial Asthma and Chronic Bronchitis in Germany

Cited by 8 publications

References 0 publications

Asthma severity and medical resource utilisation

Asthma severity and medical resource utilisation

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1‐yr retrospective study

First approaches to the monetary impact of environmental health disturbances in Germany

Contact Info

Product

Resources

About